The role of microparticles in the pathogenesis of rheumatic diseases

Christian Beyer1, David S Pisetsky

  • 1Department for Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.

Insights

Microparticles (MPs), small vesicles released from cells, are increasingly recognized for their role in rheumatic diseases, impacting thrombosis and inflammation. Elevated MP levels in blood may serve as novel biomarkers for assessing disease activity in affected tissues.

Area of Science:

  • Rheumatology
  • Vascular Biology
  • Cell Biology

Background:

  • Microparticles (MPs) are vesicles released during cell activation and apoptosis.
  • MPs possess pleiotropic effects influencing thrombosis, vascular reactivity, angiogenesis, and inflammation.
  • These vesicles carry bioactive molecules, including proteins, lipids, and nucleic acids.

Purpose of the Study:

  • To highlight the emerging role of MPs in the pathogenesis of rheumatic diseases.
  • To underscore the potential of MPs as biomarkers for disease assessment.
  • To suggest future research directions for understanding MP function and therapeutic targeting.

Main Methods:

  • Review of existing literature on microparticle function in rheumatic diseases.
  • Analysis of MP composition and their transfer of molecules to target cells.
  • Evaluation of MPs as potential diagnostic and prognostic indicators.

Main Results:

  • MPs contribute to thrombosis, vascular dysfunction, and inflammation in rheumatic conditions.
  • MPs act as platforms for enzymatic processes, particularly in thrombosis.
  • Increased MP levels in circulation correlate with rheumatic disease activity.

Conclusions:

  • Microparticles play a significant pathogenetic role in rheumatic diseases.
  • Circulating MPs represent promising novel biomarkers for assessing disease status.
  • Targeting MP release or signaling pathways may offer future therapeutic strategies.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...